CytoReason unveils LINA, an AI Agent accelerated by NVIDIA for Pharma R&D, built on computational disease models
TEL AVIV, Israel, Jan. 12, 2026 /PRNewswire/ — At the 2026 JP Morgan Healthcare Conference, CytoReason unveiled LINA, an AI agent designed to support pharmaceutical research and development. LINA is a computational biology assistant that interprets molecular, clinical, and patient-level data using CytoReason’s AI disease models and NVIDIA NIM microservices. Built on CytoReason’s AI framework and trained on hundreds of […]
CytoReason extends its collaboration with Sanofi to advance AI-driven drug discovery
This marks CytoReason’s fifth commercial deal of 2025 and builds on its track record with half of the world’s top twenty pharma companies, which have leveraged its technology across a range of programs. TEL AVIV, Israel, Jan. 9, 2026 /PRNewswire/ — CytoReason, a leader in AI-powered computational disease modeling, today announced the expansion of its collaboration with […]
CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
CytoReason and the Crohn’s & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research
CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal
Poolbeg Pharma reaches R&D milestone as partner CytoReason completes AI influenza disease model
CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers
CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development
Cytoreason and Summit Pharmaceuticals International forge commercial alliance to bring CytoReason’s machine learning model of the immune system for drug discovery & development to Japanese drug makers
